Clinical trial
Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and…
NCT00095706 · Translational Oncology Research International, Other · Completed
Key facts
| NCT number | NCT00095706 |
|---|---|
| Title | Treatment of HER2-Positive Metastatic Breast Cancer With Herceptin and Bevacizumab (Antibodies Against HER2 and VEGF) |
| Official title | Phase I/II Combined Biological Therapy of Breast Cancer Using Monoclonal Antibodies Directed Against HER2/Neu Proto-Oncogene and Vascular Endothelial Growth Factor |
| Lead sponsor | Translational Oncology Research International, Other |
| Collaborators | Genentech, Inc. Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Bevacizumab (drug), Herceptin (drug) |
| Enrollment | 50 |
| Start date | Jun 1, 2003 |
| Primary completion | Apr 1, 2007 |
| Completion | Jan 1, 2012 |
| First posted | Nov 8, 2004 |
| Last update posted | Sep 25, 2015 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: